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Background:  Non-typeable  Haemophilus  inﬂuenzae  (NTHi)  is a major  cause  of  various  respiratory  diseases.
The  development  of  an  effective  vaccine  against  NTHi  mandates  new  approaches  beyond  conjugated
vaccines  as this  opportunistic  bacterium  is  non-encapsulated.  Here  we  report  on  the  safety,  reactogenicity
and  immunogenicity  of  a multi-component  investigational  vaccine  based  on  three  conserved  surface
proteins  from  NTHi  (proteins  D  [PD],  E [PE]  and  Pilin  A  [PilA])  in  two observer-blind  phase  I studies.
Methods:  In the  ﬁrst  study  (NCT01657526),  48 healthy  18–40 year-olds  received  two  vaccine  formu-
lations  (10  or  30 g of  each  antigen  [PD  and  a  fusion  protein  PE-PilA])  or saline  placebo  at  months  0
and  2.  In the  second  study  (NCT01678677),  270  50–70  year-olds,  current  or former  smokers,  received
eight  vaccine  formulations  (10 or  30 g antigen/dose  non-adjuvanted  or  adjuvanted  with  alum,  AS01E
or  AS04C) or  saline  placebo  at months  0,  2 and  6 (plain  and  alum-adjuvanted  groups)  and  at  months  0
and  2 (AS-adjuvanted  groups).  Solicited  and unsolicited  adverse  events  (AEs)  were  recorded  for  7  and
30 days  post-vaccination,  respectively;  potential  immune-mediated  diseases  (pIMDs)  and  serious  AEs
(SAEs)  throughout  the  studies.  Humoral  and  antigen-speciﬁc  T-cell  immunity  (in study  2 only)  responses
were  assessed  up  to  12 months  post-vaccination.
Results:  Observed  reactogenicity  was highest  in  the AS-adjuvanted  groups  but no  safety  concerns  were
identiﬁed  with  any  of  the  NTHi  vaccine  formulations.  One  fatal  SAE  (cardiac  arrest)  not considered  related
to  vaccination,  and one  pIMD  (non-serious  psoriasis)  in the Placebo  group,  were  reported  post-dose  3  in
Study 2.  All formulations  generated  a robust  antibody  response  while  the AS01-adjuvanted  formulations
produced  the  highest  humoral  and cellular  immune  responses.
Conclusion:  This study  conﬁrms  that  the  NTHi  vaccine  formulations  had  an  acceptable  reactogenicity  and
safety  proﬁle  and  were  immun
NTHi  vaccine  candidate.
©  2016  The  Authors.  Publis
Abbreviations: AEs, adverse events; ATP, according-to-protocol; CIs, conﬁdence interv
LISA  units; GMCs, geometric mean concentrations; GMTs, geometric mean titers; ICS, in
eripheral blood mononuclear cells; PD, protein D; PE, protein E; PilA, Pilin A; pIMDs,
accinated cohort.
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. Introduction
Non-typeable Haemophilus inﬂuenzae (NTHi) is an opportunistic
athogen and a major cause of various respiratory diseases includ-
ng otitis media, sinusitis, conjunctivitis, community-acquired
neumonia and exacerbations of chronic obstructive pulmonary
isease (COPD) [1,2]. An increase in NTHi prevalence as an etio-
ogical factor of invasive infections has been observed, especially
mong immunocompromised individuals and the adults [3–5].
ith older age, comorbidities and immunosenescence are com-
on  risk factors for severe infections [6,7]. Another risk factor in
dults is smoking, which interferes with mucociliary clearance,
iminishes the inﬂammatory cytokine response and disrupts the
pithelial barrier [8,9].
NTHi infections are responsible for considerable morbidity and
ealthcare costs while NTHi exacerbations of COPD are also asso-
iated with signiﬁcant mortality rates [10–12]. Antibiotics should
e the ﬁrst line treatment of NTHi infections, but increasing antibi-
tic resistance has been observed [13]. An effective vaccine against
THi could circumvent this issue, but its development remains a
hallenge since NTHi is a non-encapsulated bacterium (in contrast
o typeable H. inﬂuenzae strains) that does not present at the sur-
ace polysaccharide chains which could be used as vaccine antigens.
herefore, surface-exposed proteins represent important NTHi vac-
ine and diagnostic targets [14,15].
We developed a new NTHi multi-component investigational
accine, based on 3 selected conserved surface proteins in the form
f 2 vaccine antigens: a free recombinant protein D (PD) and a
ecombinant fusion protein combining protein E and Pilin A (PE-
ilA). PD is a highly conserved lipoprotein among encapsulated
nd non-encapsulated H. inﬂuenzae strains [16]. PD is also used as
arrier in the licensed pneumococcal polysaccharide PD-conjugate
accine (PHiD-CV, SynﬂorixTM; GSK Vaccines, Rixensart, Belgium)
17]. PE, a highly conserved protein in NTHi, is involved in adhe-
ion and human complement resistance [18–21], while PilA plays a
ole in bioﬁlm formation, adherence to human epithelial cells and
olonization of the upper respiratory tract [22].
On top of the classical aluminum hydroxide (alum)-based
pproach, we have assessed the potential beneﬁt of including an
djuvant System (AS01 or AS04) in the investigational vaccine, to
ventually overcome immunosenescence or impaired immunity in
ertain target populations [23].
Here we report the safety, reactogenicity and immunogenicity
esults of two phase I trials following administration of 2 or 3 doses
f different formulations of NTHi investigational vaccine in adults.
. Methodology
.1. Studies design and participants
Study 1 was a ﬁrst-time-in-humans, phase I, randomized,
bserver-blind, placebo-controlled, single-center, dose-escalation
tudy, conducted in Australia, between 08 August 2012 and 25
ovember 2013. Healthy 18–40 year-olds were enrolled in a stag-
ered manner in 2 steps and randomized using a centralized
andomization system on internet (SBIR) (2:1 per step) to receive
 doses of an NTHi formulation (10 g of each antigen [PD and PE-
ilA] in step 1 [10-PLAIN group] or 30 g of each antigen in step 2
30-PLAIN group]) or saline placebo at months 0 and 2.
Study 2 was a phase I, randomized, observer-blind, placebo-
ontrolled, dose-escalation study, conducted in 3 centers in
elgium, between 31 August 2012 and 30 January 2014. Current
nd former smokers, 50–70 years old, were enrolled in a stag-
ered manner in 2 steps and randomized using SBIR (2:2:2:2:1 per
tep) to receive 2 or 3 doses of an NTHi vaccine out of 8 different 34 (2016) 3156–3163 3157
formulations (10 g of antigen per dose in step 1 and 30 g of
each antigen per dose in step 2, either non-adjuvanted [plain] or
adjuvanted with alum, AS01E or AS04C [10-PLAIN, 10-AL, 10-AS01,
10-AS04, 30-PLAIN, 30-AL, 30-AS01 and 30-AS04 groups]) or saline
placebo at months 0, 2 and 6 for plain and alum-adjuvanted groups
and at months 0 and 2 for AS-adjuvanted groups. The participants
from the AS-adjuvanted groups received saline placebo at month
6.
These studies were observer-blind, i.e. the vaccine recipients
and those responsible for the evaluation of any study endpoint
were blinded to the administered vaccines. Due to differences in
the appearance of the study vaccines, vaccines were prepared and
administered by authorized medical personnel who did not partic-
ipate in any of the study clinical evaluations or assays.
The inclusion and exclusion criteria are detailed in
Supplementary methods.
The studies were conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice. The protocols
and associated documents were reviewed and approved by an
independent ethics committee. All participants provided writ-
ten informed consent prior to study entry. These studies have
been registered at www.clinicaltrials.gov (NCT01657526 and
NCT01678677). Protocol summaries are available at http://www.
gsk-clinicalstudyregister.com (GSK studies 116018 and 116647).
2.2. Studies objectives
The primary objective was  to evaluate the safety and reacto-
genicity proﬁle of the NTHi vaccine formulations. The secondary
objectives were to evaluate: the antibody and cell mediated
immune (CMI) (Study 2 only) responses to PD, PE and PilA induced
by the vaccine formulations prior to, and at 30 days after each vacci-
nation (both studies); and the persistence of the immune responses
up to 12 months post-dose 2 (i.e. Day 420).
2.3. Study vaccines
Eight formulations were assessed: 10 or 30 g antigen (PD and
PE-PilA) per dose with or without adjuvant. NTHi PD and PE-
PilA fusion protein were prepared using recombinant strains of
Escherichia coli, followed by protein puriﬁcation and sterile ﬁltra-
tion. A detailed description of vaccine presentation and adjuvants
is given in Supplementary.
2.4. Reactogenicity and safety
Data were collected in an observer-blind manner (details given
in Supplementary).
Diary cards were used to record solicited local (pain, redness
and swelling) and general adverse events (AEs) (fatigue, headache,
gastrointestinal symptoms, fever) for 7 days after each vaccine dose
and unsolicited AEs for 30 days after each dose. AE intensity was
graded on a 1–3 scale. Redness or swelling of diameter >100 mm,
temperature >39.5 ◦C and other AEs that prevented normal activi-
ties were considered as Grade 3.
Data regarding any pregnancy, new medical condition requiring
medical attention, potentially immune mediated diseases (pIMDs)
and serious AEs (SAEs) were collected throughout the studies.
Hematological and biochemical parameters were measured to
assess the subject eligibility at screening, and at Days 7, 60, 67,
180, 187, and 420. Abnormal laboratory ﬁndings or other assess-
ments (e.g. abnormal blood pressure) judged by the investigator to
be clinically signiﬁcant were recorded as AE or SAE.
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Total vaccinated cohort (N=48)
30-PLAIN
N=16
ATP cohortimmunogenicity (N=28)
10-PLAIN
N=16
Placebo
N=16
N=11
Reason for exclusion:
• Non-compliance with 
vaccination schedule (1)
• Non-compliance with blo od 
sampling schedule (4)
N=8
Reason for exclusion:
• Non-compliance with blood 
sampling schedule (7)
• Essential serological data 
missing (1)
N=9
Reason for exclusion:
• Non-compliance with 
vaccination schedule (2)
• Non-compliance with blo od 
sampling schedule (5)
Total vaccinated cohort (N=270)
10-AS01
N=30
ATP cohortimmunogenicity (N=240)
30-AL
N=31
30-AS01
N=30
N=25
Reason for exclusion:
• Administration of 
vaccine forbidden in 
the protocol (1)
• Non-compliance with 
vaccination schedule 
(1)
• Non-compliance with 
blood sampling 
schedule (1)
• Essential se rological 
data missing (1)
N=25
Reason for exclusion:
• Administration of 
vaccine forbidden in 
the protocol (2)
• Administration of any 
medication forbidden 
by the protocol (1)
• Non-compliance with 
vaccination schedule 
(1)
• Non-compliance with 
blood sampling 
schedule (1)
N=23
Reason for exclusion:
• Administration of 
vaccine forbidden in 
the protocol (2)
• Non-compliance with 
blood sampling 
schedule (2)
• Essential serological 
data missing (3)
30-AS04
N=30
10-AS04
N=30
Placebo
N=30
30-PLAIN
N=29
10-PLAIN
N=31
10-AL
N=29
N=28
Reason for exclusion:
• Administration of 
vaccine forbidden in 
the protocol (1)
• Ran domization 
failure (1)
• Protocol violation (1)
N=27
Reason for exclusion:
• Protocol violation (1)
• Non-compliance with 
blood sampling 
schedule (1)
N=30
Reason for exclusion:
• Administration of 
vaccine forbidden in 
the protocol (1)
N=25
Reason for exclusion:
• Administration of any 
medication forbidden 
by the protocol (1)
• Non-compliance with 
blood sampling 
schedule (1)
• Essential serological 
data missing (3)
N=30 N=27
Reason for exclusion:
• Non-compliance with 
blood sampling 
schedule (1)
• Essential serological 
data missing (2)
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Aig. 1. Disposition of study participants and reasons for exclusion from according-to
B).  N: number of participants; ATP: according-to-protocol.
.5. Humoral and cellular immunogenicity
Blood samples for immunogenicity were taken prior to, and at
0 days after each vaccination, and at 12 months post-dose 2 (i.e.
ays 0, 30, 60, 90, 180, 210 and 420).
The anti-PD, anti-PE and anti-PilA antibody concentrations were
easured by ELISA, using standardized procedures. The cut-off of
he assays was 100 ELISA units (EU)/mL, 8 EU/mL and 7 EU/mL for
nti-PD, anti-PE and anti-PilA, respectively.
CMI  responses (antigen-speciﬁc CD4+ and CD8+ T-cells) were
easured only in Study 2, by ﬂow cytometry using intracellular
ytokine staining (ICS) on frozen peripheral blood mononuclear
ells (PBMCs), following an adaptation of previously described
ethods [24]. After PBMC stimulation with the relevant antigens,
he frequency of CD4+ and/or CD8+ T-cells expressing a selected
et of cytokines (IL-2, IL-13, IL-17, IFN-, TNF- and CD40L) or a
elected combination of cytokines was evaluated.
.6. Statistical analysis
The safety analysis was performed on the total vaccinated cohort
TVC), which included all vaccinated participants. The incidence
f AEs per study group was tabulated with exact 95% conﬁdence
ntervals (CIs) after each vaccine dose and overall. All SAEs, with-
rawals due to AE(s), pIMDs, pregnancies and all treatment-related
Es were described in detail.ocol cohort for immunogenicity: Study 1 until Day 90 (A) and Study 2 until Day 420
The immunogenicity analysis was based on the according-to-
protocol (ATP) cohort for immunogenicity. Seropositivity rates,
geometric mean concentrations (GMCs) and geometric mean titers
(GMTs) with their 95% CIs were calculated for each study group.
Details on the statistical analysis of antibody responses, GMC  ratios
and CMI  responses (Study 2) are given in Supplementary methods.
3. Results
3.1. Demographics
In Study 1, 48 healthy adults were enrolled and vaccinated, and
46 completed the study (1 consent withdrawal and 1 loss to follow-
up). Twenty participants were excluded from the ATP cohort for
immunogenicity, mainly because of non-compliance with blood
sampling schedule (Fig. 1A). Mean age at ﬁrst vaccination was 27.0
years; 64.6% were women; the majority (95.8%) was of Caucasian
origin (Table 1).
In Study 2, 270 (former) smokers were enrolled and vaccinated,
and 257 completed the study (13 withdrawals: 9 consent with-
drawals, 3 due to SAEs [1 cardiac arrest, 1 traumatic intracranial
hemorrhage and 1 myocardial infarct] and 1 protocol violation
[medical history of psoriasis]). Thirty participants were excluded
from the ATP cohort for immunogenicity, mainly due to: essen-
tial serological data missing (9 participants), administration of
vaccine(s) forbidden by the protocol (7 participants) and non-
compliance with the blood sampling schedule (7 participants)
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Table  1
Demographics of healthy adults (Study 1) (total vaccinated cohort).
Group 10-PLAIN N = 16 30-PLAIN N = 16 Placebo N = 16
Mean age, years (SD) 28.5 (6.85) 26.9 (6.82) 25.7 (7.20)
Females, n (%) 9 (56.3%) 12 (75.0%) 10 (62.5%)
Asian/East or South-East Asian Heritage, n (%) 0 0 2 (12.5%)
White-Caucasian/European Heritage/, n (%) 16 (100%) 16 (100%) 14 (87.5%)
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eceived a saline solution; N, number of participants; n (%), number and percentage
Fig. 1B). Mean age at ﬁrst vaccination was 59.4 years; 47.8% were
omen; 58.9% were current smokers; the majority (98.5%) was of
aucasian origin (Table 2).
.2. Reactogenicity and safety
In Study 1, placebo and active vaccine recipients had similar
evels of reactogenicity. Pain was the most frequently reported
olicited local AE during the 7-day post-vaccination period, with
nly one case of grade 3 pain recorded (Placebo group post-Dose
) (Supplementary Fig. 1A). In Study 2, pain at the injection site
as also the most frequently reported solicited local AE (Fig. 2A),
ith higher percentages observed in the AS-adjuvanted (point
stimates >75%) vs. the plain and alum-adjuvanted groups (point
stimates <50%). There were 11 cases of grade 3 pain and 3 cases
f grade 3 redness, all recorded post-Dose 2 in AS-adjuvanted
ecipients.
During the 7-day post-vaccination period, headache and fatigue
ere the most frequently reported solicited general AEs in
oth Study 1 (<62.5% of 30-PLAIN participants post-dose 1)
Supplementary Fig. 1B) and Study 2 with high percentages
bserved in both 10- and 30-AS01 groups and in the 30-AS04 group
point estimates >20% post-Dose 1 or 2) (Fig. 2B). In Study 1, 3 grade
 general AEs cases were reported: 2 fatigue cases (1 post-Dose 1
n Placebo and 1 post-Dose 2 in the 30-PLAIN group) and 1 grade 3
astrointestinal symptoms post-Dose 1 in Placebo. In Study 2, there
ere 19 grade 3 cases (6 fatigue, 7 gastrointestinal symptoms and
 headache cases) reported in Placebo (6), AS01 (8), AS04 (3) and
able 2
emographics of (former) smokers (Study 2) (total vaccinated cohort).
Group 10-PLAIN N = 31 30-PLAIN N = 29 10-AL N = 29 30-AL N = 31 1
Mean age, years
(SD)
57.7 (5.77) 59.8 (4.95) 59.9 (5.23) 60.0 (5.95) 5
Females, n (%) 17 (54.8%) 13 (44.8%) 14 (48.3%) 20 (64.5%) 1
Current smoker 19 (61.3%) 17 (58.6%) 17 (58.6%) 17 (54.8%) 1
African-
American/African
Heritage, n (%)
0 2 (6.9%) 0 0 
Asian/Central-
South Asian
Heritage, n (%)
0 0 0 0 
White-Caucasian/
European
Heritage, n (%)
31 (100%) 27 (93.1%) 29 (100%) 31 (100%) 2
White-Caucasian/
European
Heritage, n (%)
31 (100%) 27 (93.1%) 29 (100%) 31 (100%) 2
0-PLAIN indicates participants who received 10 g/antigen/dose; 30-PLAIN indicates 
eceived 10 g/antigen/dose adjuvanted with alum; 30-AL indicates participants who  re
ho  received 10 g/antigen/dose adjuvanted with AS01E; 30-AS01 indicates participan
articipants who received 10 g/antigen/dose adjuvanted with AS04C; 30-AS04 indicate
ndicates participants who received a saline solution; N, number of participants; n (%), nuarticipants who received 30 g/antigen/dose; Placebo indicates participants who
rticipants in a speciﬁc category; SD, standard deviation.
in Alum groups (2); 11 out of 19 cases (57.9%) occurred post-Dose
2.
In Study 1, at least one unsolicited AE was reported by 42/48
(87.5%) of the participants during the 30-day post-vaccination
period. Headache (14/48 [29.2%]) and oropharyngeal pain (8/48
[16.7%]) were the most frequently reported unsolicited AEs both
in placebo and vaccine groups. No grade 3 vaccine-related unso-
licited AEs were reported. In Study 2, 51.7–80.0% of the participants
reported unsolicited AEs post-Dose 1, 2 and/or 3. Nasopharyngitis
and headache were the most frequently reported unsolicited AEs.
There were 2 cases of grade 3 vaccine-related unsolicited AEs: 1
hypersensitivity case in the 10-AS01 group post-Dose 2 (started 1
day post-vaccination and lasted 4 days) and 1 upper respiratory
tract infection in the 30-AS04 group post-Dose 1 (started the day
of vaccination and lasted 19 days).
SAEs, unrelated to vaccination, were reported by 2 and 24 partic-
ipants in Studies 1 and 2, respectively. In Study 2, one fatal SAE was
reported in the 30-PLAIN group (cardiac arrest; 50 days post-Dose
3) and 3 other SAE cases did not resolve by Day 420 (1 chronic lym-
phocytic leukemia, 1 cardiac failure and 1 traumatic intracranial
hemorrhage). One pIMD (non-serious psoriasis) considered related
to vaccination was  reported at 114 days post-Dose 3 in the Placebo
group.
No clinically relevant laboratory abnormalities were observed
during Study 1. In Study 2, grade 3 changes in hematological and
biochemical levels were reported by a maximum of 2 partici-
pants per group (details in Supplementary). A grade 4 neutropenia
(<500 cells/mm3) was  reported for 1 participant in the 10-PLAIN
group at Day 420 (8 months post-Dose 3).
0-AS01 N = 30 30-AS01 N = 30 10-AS04 N = 30 30-AS04 N = 30 Placebo N = 30
9.3 (5.96) 59.7 (4.85) 59.4 (5.74) 60.0 (6.21) 59.1 (5.06)
4 (46.7%) 15 (50.0%) 9 (30.0%) 17 (56.7%) 10 (33.3%)
8 (60.0%) 17 (56.7%) 19 (63.3%) 17 (56.7%) 18 (60.0%)
0 0 1 (3.3%) 0 0
1 (3.3%) 0 0 0 0
9 (96.7%) 30 (100%) 29 (96.7%) 30 (100%) 30 (100%)
9 (96.7%) 30 (100%) 29 (96.7%) 30 (100%) 30 (100%)
participants who received 30 g/antigen/dose; 10-AL indicates participants who
ceived 30 g/antigen/dose adjuvanted with alum; 10-AS01 indicates participants
ts who  received 30 g/antigen/dose adjuvanted with AS01E; 10-AS04 indicates
s participants who  received 30 g/antigen/dose adjuvanted with AS04C; Placebo
mber and percentage of participants in a speciﬁc category; SD, standard deviation.
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Fig. 2. Solicited local (A) and general (B) symptoms reported during the 7-day post-vaccination period in Study 2 (Total vaccinated cohort). 10-PLAIN indicates participants
who  received 3 doses of NTHi at 10 g/antigen/dose; 30-PLAIN indicates participants who received 3 doses of NTHi at 30 g/antigen/dose; 10-AL indicates participants
who  received 3 doses of NTHi at 10 g/antigen/dose adjuvanted with alum; 30-AL indicates participants who received 3 doses of NTHi at 30 g/antigen/dose adjuvanted
with  alum; 10-AS01 indicates participants who received 2 doses of NTHi at 10 g/antigen/dose adjuvanted with AS01E and one dose of saline placebo; 30-AS01 indicates
participants who received 2 doses of NTHi at 30 g/antigen/dose adjuvanted with AS01E and one dose of saline placebo; 10-AS04 indicates participants who received 2 doses
of  NTHi at 10 g/antigen/dose adjuvanted with AS04C and one dose of saline placebo; 30-AS04 indicates participants who received 2 doses of NTHi at 30 g/antigen/dose
adjuvanted with AS04C and one dose of saline placebo; Placebo indicates participants who  received a saline solution; PRE, pre-Dose 1; PI(D30), 30 days post-Dose 1; PI(D60),
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.3. Immunogenicity
.3.1. Antibody response
In Study 1, GMCs for anti-PD, anti-PE and anti-PilA antibodies
ncreased up to Day 90 after each active dose compared to placebo
except for anti-PD in PLAIN groups) (Supplementary Fig. 2).
In Study 2, the AS01-adjuvanted formulations generated the
ighest observed GMCs (Fig. 3). For PE and PilA, antibody responses
fter 2 doses of the AS01-adjuvanted formulations were higher
ompared to the responses after 3 doses of the alum-adjuvanted
ormulations (lower limits of the 95% CIs of GMC  ratios were >2).
n all AS-adjuvanted groups, no clear antigen-dose effect could beost-Dose 3; PIII(D420), 8 months post-Dose 3. N = number of documented doses;
ﬁdence interval; GI = gastrointenstinal.
observed in antibody responses. The GMCs at Day  420 remained
much higher compared to pre-vaccination levels in all active
groups. Results remained similar when the analysis was done on
the TVC.
In Study 2, immunogenicity was also presented per group by
smoking status: similar immunogenicity responses were observed
for current smokers and ex-smokers (data not shown).3.3.2. Antigen-speciﬁc CD4+ and CD8+ T-cells (Study 2)
The speciﬁc CD4+ T-cell responses for all NTHi vaccine formu-
lations are presented in Fig. 4. The observed CMI responses in the
AS01 groups were the highest. In the AS-adjuvanted groups, there
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with  alum; 10-AS01 indicates participants who received 2 doses of NTHi at 10 g/antigen/dose adjuvanted with AS01E and one dose of saline placebo; 30-AS01 indicates
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as a trend for CD40L, IL-2, TNF- and to a lesser extent IFN-,
L-13 and IL-17 expression (Supplementary Fig. 3).
No clear antigen-dose effect could be observed. A waning of
he response was seen after the second dose in the AS-adjuvanted
roups, but the response at Day 420 remained much higher than
he pre-vaccination levels. A third dose of plain or alum-adjuvanted
accine formulation did not change the levels of the observed cel-
ular response (Fig. 4).
No detectable speciﬁc CD8+ T-cell responses were observed
data not shown).
. Discussion
The present studies were primarily designed to assess the safety,
eactogenicity and immunogenicity of a new NTHi vaccine candi-
ate based on well conserved surface and virulence factors (PD and
E-PilA) in adults.
Animal studies have shown that PD has induced protection
gainst NTHi otitis media in rat and chinchilla models [14]. While
nti-PD antibodies have been linked to clinical protection against
titis media in children [17], the role of anti-PD antibodies in pro-
ection against pulmonary or systemic infections caused by NTHi
n adults is yet not known despite the fact that anti-PD antibodies
ay  impair bacterial adherence and phosphorylcholine decoration
25]. A recent phase I study indicated that a tri-protein investi-
ational vaccine, including PD and 2 pneumococcal proteins, was
mmunogenic in healthy adults (18–40 year-olds) [26].
No safety concerns were identiﬁed with any of the NTHi vac-
ine formulations tested. In Study 1, similar levels of reactogenicity
local and systemic) were observed both in placebo and active
accine recipients. In Study 2, there were higher frequencies of
eported AEs in the AS groups.
The higher local and systemic reactogenicity to the AS-
djuvanted formulations may  be due to the fact that adjuvants
ead to an enhanced migration of monocytes and macrophages
o the injection site and an increased production of cytokines
nd chemokines [27,28]; other adjuvanted formulations have
een shown to be more reactogenic than non-adjuvanted vaccine-AS04 indicates participants who  received 2 doses of NTHi at 30 g/antigen/dose
 received a saline solution; PRE, pre-Dose 1; PI(D30), 30 days post-Dose 1; PI(D60),
t-Dose 3; PIII(D420), 8 months post-Dose 3.
formulations [26,29,30]. Our phase I studies enrolled a limited
number of subjects, and thus no formal statistical comparisons
of reactogenicity between groups were performed. However, no
major differences in the frequency of Grade 3 solicited AEs between
adjuvanted and non-adjuvanted vaccine groups and no clear dose-
related increases in reactogenicity were observed in Study 2.
Robust and persistent antibody responses post-Dose 1, with a
substantial increase post-Dose 2 for the adjuvanted formulations
(up to 3.2-fold for PD, 11.6-fold for PE and 10.8-fold for PilA in the
30-AS01 group) and a further increase post-Dose 3 in the alum-
adjuvanted groups (up to 2.1-fold for PD, 4.3-fold for PE and 2.0-fold
for PilA) were observed. After 2 doses, immune responses in the AS-
adjuvanted groups were higher than in the other groups, with the
AS01-adjuvanted formulation inducing the highest response. After
3 doses with alum-adjuvanted or plain formulations, the immune
responses were lower than those following the administration of
2 doses of the AS01-adjuvanted formulation. Although an AS03-
adjuvanted pandemic inﬂuenza vaccine has been shown to allow
for antigen sparing [31], in our case no clear antigen-dose effect
could be observed with the AS01 formulation and the one observed
with the other formulations was limited. However, these compar-
isons were exploratory and have to be interpreted with caution
considering that there was no adjustment for multiplicity. As per
design, there was no way to dissociate step effect and dose effect
(the participants were enrolled in 2 steps and the lower dose for-
mulation was  given in the ﬁrst step), and therefore it was assumed
that there was no step effect.
The CMI  response in terms of CD4+ T-cells expressing at least
two markers amongst IL-2, IFN-, IL13, IL17, TNF- and CD40L
was very low for the plain and for the alum-adjuvanted formu-
lations (especially for PD and PilA). A third dose did not impact
the CMI  responses for these NTHi formulations. The AS-adjuvanted
formulations induced the highest CMI  response, with a substan-
tial increase post-Dose 2. No clear antigen-dose effect could be
observed with any of the NTHi formulations. One of the causes of the
low CMI  response (especially in the plain formulations) may  be the
older age of the participants in Study 2. Age-associated immunose-
nescence is known to cause a decline in the total number of T-cells
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Fig. 4. Frequency (%) of PD (A), PE (B) and PilA (C) speciﬁc CD4+ T-cells expressing at least 2 markers amongst IL-2, IFN-, IL-13, IL-17, TNF- and CD40L, prior and after each
vaccination (according-to-protocol cohort for immunogenicity). 10-PLAIN indicates participants who received 3 doses of NTHi at 10 g/antigen/dose; 30-PLAIN indicates
participants who  received 3 doses of NTHi at 30 g/antigen/dose; 10-AL indicates participants who  received 3 doses of NTHi at 10 g/antigen/dose adjuvanted with alum;
30-AL  indicates participants who received 3 doses of NTHi at 30 g/antigen/dose adjuvanted with alum; 10-AS01 indicates participants who received 2 doses of NTHi at
10  g/antigen/dose adjuvanted with AS01E and one dose of saline placebo; 30-AS01 indicates participants who received 2 doses of NTHi at 30 g/antigen/dose adjuvanted
with  AS01E and one dose of saline placebo; 10-AS04 indicates participants who received 2 doses of NTHi at 10 g/antigen/dose adjuvanted with AS04C and one dose of
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saline  placebo; 30-AS04 indicates participants who received 2 doses of NTHi at 30 
articipants who received a saline solution; PRE, pre-Dose 1; PI(D30), 30 days po
III(D210), 30 days post-Dose 3; PIII(D420), 8 months post-Dose 3; Min/Max, minim
nd to compromise the T-cell repertoire and function [32,33]. Alter-
tions of the immune system of adult smokers may  be an additional
ause of the low immune responses in our case [8,9]. Nicotine from
he cigarette smoke is the main inhibitor of both the innate and
daptive immune responses [8].
As expected [23], the induced response to vaccination was
mproved by the use of adjuvants. In our case, the highest CMI
esponse was observed for the AS01E-adjuvanted formulations. The
igh humoral and CMI  response for the AS01E-adjuvanted formula-
ions was not surprising since the capacity of AS01-based adjuvants
o strongly enhance the immune responses was previously demon-
trated in various clinical studies [34,35]. The inclusion of another
S containing MPL  and QS-21 (AS02v) in a pneumococcal protein
htD vaccine was previously shown to partially restore the reduced
mmune response to vaccines among older adults to the level of
accine-induced response observed in younger adults [30].
Functional characterization of the T-cells upon vaccination
howed a trend for a dominant CD4+ Th0/Th1 cytokine proﬁle, withigen/dose adjuvanted with AS04C and one dose of saline placebo; Placebo indicates
se 1; PI(D60), pre-Dose 2; PII(D90), 30 days post-Dose 2; PII(D180), pre-Dose 3;
aximum; Q1 and Q3, ﬁrst and third quartiles.
CD40L, Il-2 and TNF- expression, and low levels of IFN-; very
low CD4+ Th2 or Th17 and no CD8+ T-cell induction was observed.
For the AS01-adjuvanted formulation, these results are in line with
previously shown responses in adults [36].
In conclusion, the new NTHi vaccine formulations have an
acceptable reactogenicity, safety and immunogenicity proﬁle in
a limited number of adults per vaccine group. All formulations
generated a robust antibody response while the AS01-adjuvanted
formulations were shown to produce the highest humoral and CMI
response. These results justify further clinical assessment of the
new NTHi vaccine formulations.
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